Stock futures are little changed on Tuesday as investors await news from a press conference Wednesday with President-elect Donald Trump. Oil prices level off. Pluristem Therapeutics (PSTI) stock is popping in mid-morning trading on …
Jeffrey Sachs
HC Wainwright reiterated their buy rating on shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) in a research note issued to investors on Monday morning. The brokerage currently has a $3.50 price objective on the biotechnology …
BNS7d
Wainwright
Pluristem Therapeutics, Inc. (NASDAQ:PSTI)’s technical analysis of the stock outlines its trading $-0.100 points away or -7.144%, which is away from its 50-day moving average of $1.396. It is also an additionally trading of $-0.062 or -4.563% …
As of late, it has definitely been a great time to be an investor in Pluristem Therapeutics Inc. PSTI. The stock has moved higher by 25.6% in the past month, while it is also above its 20 Day SMA too. This combination of strong price …
NASDAQ1mon
NASDAQ
Bottom line: The Bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $2.84M - other expenses = $-23.24M for PSTI stock. An improving bottomline implies that the company is …
For those that like stocks on-the-go, Pluristem Therapeutics (PSTI) has a pipeline that is already churning out statistically significant results and is well on its way to becoming a richly valued, premium stock. Investors just need to pay …
Acute radiation syndrome
Pluristem Therapeutics Inc.’s stock is down -63.25% over the last 200 days. It has underperformed the S&P 500 Index, which has decreased -0.25% over the same time. According to data compiled by Thomson Reuters, Pluristem …
Pluristem Therapeutics Inc. (NASDAQ:PSTI)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report released on Friday, May 5th. They currently have a $3.50 target price on the biotechnology company’s stock. HC …
Pluristem Therapeutics Inc. (NASDAQ:PSTI)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report issued on Monday. They presently have a $3.50 target price on the biotechnology company’s stock. HC …